(Q35843663)

10 August 2017

1 reference

title

Pemetrexed: a novel antifolate agent enters clinical practice (English)

1 reference

10 August 2017

Victoria Kut

1

1 reference

10 August 2017

Jyoti D Patel

series ordinal

2

1 reference

10 August 2017

Athanassios Argiris

series ordinal

3

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Expert Review of Anticancer Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

511-522

1 reference

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

A phase II trial of pemetrexed in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.511

21 January 2018

Identifiers

DOI

10.1586/14737140.4.4.511

1 reference

10 August 2017

1 reference